Glenmark Pharmaceuticals Ltd Share Price (GLENMARK)

Delhi High Court Restrains Glenmark from Selling Asthma Drug - 17 Apr, 2024

The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet. The court ruled that the mark is identical or deceptively similar to Sun Pharma Laboratories' registered mark for its anti-diabetes drug Istamet XR CP.

Glenmark Recalls High Blood Pressure Medication in US Market - 15 Apr, 2024

Glenmark Pharmaceuticals' US subsidiary is recalling a batch of Diltiazem Hydrochloride extended-release capsules used to treat high blood pressure in the American market. The recall was initiated after an Out of Specification (OOS) result was observed during a dissolution test at the 12-month mark in a long-term stability study.

Glenmark Pharma Recalls Medication in US Market - 14 Apr, 2024

Glenmark Pharmaceuticals is recalling a specific lot of Diltiazem Hydrochloride extended-release capsules used for high blood pressure treatment from the American market due to failed dissolution specifications. The affected lot has been produced in India and is being recalled by Glenmark Pharmaceuticals Inc., based in New Jersey.

Glenmark Pharmaceuticals Recalls Diltiazem Hydrochloride Capsules - 10 Apr, 2024

Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydrochloride extended-release capsules in the US market due to failed dissolution specifications. The drug is used to treat high blood pressure.

Glenmark Recalls Blood Pressure Medication - 09 Apr, 2024

Glenmark Pharmaceuticals has recalled 6,528 bottles of Diltiazem Hydrochloride capsules used in the treatment of high blood pressure due to failed dissolution specifications. The Class II recall was initiated on March 26.

Nirma Completes Purchase of Majority Stake in Glenmark Life Sciences - 08 Apr, 2024

Nirma has acquired a 75% stake in Glenmark Life Sciences from Glenmark Pharma for INR 56,515 Mn. The deal will help Glenmark Pharma become a brand-led organization and focus on core therapeutic areas. Glenmark will retain 7.84% ownership in Glenmark Life Sciences. Debt of INR 49,530 Mn will be repaid in FY25E, saving significant interest costs and boosting earnings. Analysts have upgraded their rating on Glenmark Pharma to BUY with a target price of INR 1,266/share.

Private Companies Hold Majority Stake in Glenmark Pharmaceuticals - 05 Apr, 2024

Private companies own 47% stake in Glenmark Pharmaceuticals, with Saldanha Family Trust being the largest shareholder. The stock is up 0.77% on NSE and has gained 110.27% in the last one year.

Glenmark Pharma Benefits from Investments in Pharmaceutical Sector; Independent Directors Retire - 01 Apr, 2024

The pharmaceuticals and drugs sector exceeded expected investments, with Glenmark Pharma among the major beneficiaries. Meanwhile, four independent directors have retired from Glenmark Pharmaceuticals.

Glenmark Pharmaceuticals Stock Jumps 117% in a Year - 28 Mar, 2024

Glenmark Pharmaceuticals stock has surged by 117% to Rs 955 from Rs 439 a year ago, with a current market capitalization of Rs 26,948 crore. It has given a 12% return in 2024 so far despite posting a loss of Rs 457 crore and gross sales at Rs 8,957 crore in the first three quarters of FY24.

Glenmark Pharma's Telma Brand Gains Popularity - 27 Mar, 2024

Glenmark Pharmaceuticals' Telma brand is gaining popularity in India as it becomes known for treating hypertension and heart failure, contributing to its recent rise in stock price.